Conference Call with Neuland Laboratories Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q3FY24 & 9MFY24 results: Q3FY24 vs Q4FY23: Total Income: Rs 394.9 crore, showing a growth of 46.2% compared to Q3FY23. EBITDA: Rs 122.7 crore, increased significantly by 123.5% from Q3FY23. EBITDA Margin: 31.1%, improved by 1080 basis points (bps) from Q3FY23. PAT: Rs 80.7 crore, showing a substantial growth of 165.1% compared to Q3FY23. PAT Margin: 20.4%, increased by 910 bps from Q3FY23. EPS (Basic): Rs 62.9, reflecting a growth of 165.1% compared to Q3FY23. 9MFY24 vs 9MFY23: Total Income: Rs 1,180.8 crore, increased significantly by 50.3% compared to 9MFY23. EBITDA: Rs 362.3 crore, showing a substantial growth of 136.4% compared to 9MFY23. EBITDA Margin: 30.7%, improved by 1120 bps from 9MFY23. PAT: Rs 232.0 crore, showing a substantial growth of 195.1% compared to 9MFY23. PAT Margin: 19.6%, increased by 960 bps from 9MFY23. EPS (Basic): Rs 180.8, reflecting a growth of 195.1% compared to 9MFY23. Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We are pleased to report another quarter of strong YoY topline growth of 46% to Rs 395 crore. The EBITDA margin of 31.1% is a factor of the business mix as well as improved operational leverage. Even as we see this as a validation of Neuland’s business model, we are focused on continuously improving operations across the company. We are investing both on infrastructure and our people so that we can deliver on our long-term plans.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw healthy growth led by commercial as well as projects close to commercialization. The increasing interest from customers with exciting pipelines establishes Neuland’s reputation as a well regarded CDMO. As the quality and size of our business grows, we are gaining a better visibility of our future and planning accordingly.” Result PDF
Conference Call with Neuland Laboratories Ltd. Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q1FY24 results: Total Income of Rs 365.0 crore in Q1FY24 compared to Rs 221.7 crore in Q1FY23, up 64.7% YoY EBITDA of Rs 99.3 crore in Q1FY24 compared to Rs 29.0 crore in Q1FY23, up 242.5% YoY EBITDA margin of 27.2% in Q1FY24 compared to 13.1% in Q1FY23 , up 1,410 bps YoY PAT of Rs 62.2 crore in Q1FY24 compared to Rs 9.8 crore in Q1FY23, up 532.3% YoY PAT margin of 17.0% in Q1FY24 compared to Rs 4.4% in Q1FY23, up 1,260 bps YoY EPS (Basic) of Rs 48.5 in Q1FY24 compared to Rs 7.7 in Q1FY23, up 532.3% YoY Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “The performance this quarter is in line with our plan and is a good indicator of the business momentum within the organization. The high YoY growth had contributions from all three segments and the EBITDA margin improvement of 1,410 bps on a YoY basis reflects the change in business mix as well as operating leverage playing out. We continue to be watchful on balancing growth with profitability by having a continuous focus on cost optimization and efficient operations to capitalise on opportunities which we believe will bring us greater scale over the long term.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added, “CMS growth in Q1FY24 was driven by recently commercialized molecules as well as molecules in the pipeline. We expect more molecules to be commercialized in the medium term which will drive our future growth. We saw a couple of more milestones in terms of our regulatory track record as Unit 3 was successfully inspected by the US FDA and we had Unit-1 being audited by EDQM. While the external environment remains uncertain with funding of early-stage molecules being affected, we remain cautiously optimistic about our future growth given the strength of our portfolio.” Result PDF